达普司他有哪几个版本?分别多少钱?

Daprostat is a new type of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). Its drug versions show diversified characteristics, covering original drugs and generic drugs. The price varies significantly due to research and development costs, production countries and distribution channels. As of May 2025, the drug has not yet been launched in China and is not covered by medical insurance. Patients must obtain it through cross-border drug purchase or clinical trial channels.

What versions of daprostat are there?

The version differentiation is closely related to its research and development background, market positioning and regulatory approval path. Patients need to choose the appropriate version according to their treatment needs, financial ability and compliance requirements.

Original drug version

The original drug of dapostat is developed by GlaxoSmithKline (GSK), and its core patents cover compound structure, preparation process and clinical indications. However, because no marketing application has been submitted in China, this version has not been approved by the National Medical Products Administration (NMPA) and can only be obtained through prescriptions from overseas medical institutions.

Generic drug version

The generic drug produced by Lucius Pharmaceuticals in Laos has passed the mutual recognition process of the drug regulatory agencies of ASEAN countries. This version is available in 1 mg × 100 tablets. The dosage of a single tablet can be flexibly adjusted to 5-10 mg per day, and is suitable for maintenance treatment.

How much do the different versions of daplostat cost?

The price system of daplostat is significantly affected by R&D cost allocation, production scale effect and market access policy. Patients need to choose a purchasing plan based on the medication cycle, dose adjustment needs and compliance requirements.

Prices of original drugs

Since original drugs have not been launched in China, their price information mainly comes from overseas medical institutions, and the price is usually relatively expensive. If Chinese patients obtain it through a cross-border drug purchase platform, they need to bear tariffs, international freight and cold chain packaging fees. The final price is 40%-60% higher than the overseas selling price.

Price of generic drugs

The Laos version of Lucius’s generic version of daprostat is 1mg*100 tablets, and the price is relatively affordable, about US$6 per box.

The marketing and medical insurance status of daprostat in China

The clinical application of daprostat in China is limited by the dual constraints of not being on the market and not being covered by medical insurance. Patients need to solve the problem of treatment accessibility through alternative solutions or clinical trials.

Marketing status

As of May 6, 2025, daprostat has not submitted a marketing application to the NMPA and has not yet been approved for marketing in China. Patients cannot purchase it directly in domestic hospitals or pharmacies.

Alternatives and clinical trials

Domestic patients can participate in clinical trials to obtain daprostat, or they can apply for the "licensed drug and device" policy of Hainan Boao Lecheng International Medical Tourism Pilot Zone to use overseas marketed drugs in designated medical institutions.

Although it has not yet been officially launched in China and has not been included in medical insurance, its potential value has attracted widespread attention and is expected to provide new opportunities to improve the quality of life of patients with chronic kidney disease in my country in the future.